Apyx Medical (NASDAQ:APYX) Shares Break Above 50-Day Moving Average – Time to Sell?

Apyx Medical Corporation (NASDAQ:APYX)’s stock price passed above its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $2.74 and traded as high as $3.11. Apyx Medical shares last traded at $3.0450, with a volume of 994,957 shares traded.

Key Stories Impacting Apyx Medical

Here are the key news stories impacting Apyx Medical this week:

• Positive Sentiment: Q3 revenue was $14.0 million, above the $13.29 million analyst estimate, while the loss of $0.04 per share was narrower than consensus estimates of $0.07–$0.09. Surgical Aesthetics revenue grew 17%. Apyx Medical Q3 2026 financial results
• Positive Sentiment: Management tightened its 2026 operating expense target to $41 million–$42.5 million, indicating a greater focus on cost control. Apyx reaffirms guidance and tightens expense target
• Neutral Sentiment: Apyx reaffirmed 2026 revenue guidance of $59 million–$60 million, broadly in line with the $59.4 million consensus estimate. The company also reported a successful commercial launch of its AYON power liposuction handpiece. Apyx Medical Q3 2026 financial results
• Negative Sentiment: The company continued to post a quarterly loss and has negative net margins, so sustained revenue growth and expense control will be important to improving profitability.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on APYX shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Apyx Medical in a research report on Monday, September 21st. HC Wainwright began coverage on shares of Apyx Medical in a report on Monday, July 13th. They issued a “buy” rating and a $7.00 price objective on the stock. Zacks Research raised shares of Apyx Medical to a “hold” rating in a report on Tuesday, July 14th. Finally, Maxim Group initiated coverage on shares of Apyx Medical in a research note on Tuesday, September 29th. They issued a “buy” rating and a $6.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $6.50.

Apyx Medical Price Performance

The firm has a market cap of $128.27 million, a PE ratio of -15.22 and a beta of 1.47. The stock has a 50 day simple moving average of $2.74 and a two-hundred day simple moving average of $3.59. The company has a debt-to-equity ratio of 3.19, a quick ratio of 4.53 and a current ratio of 5.68.

Apyx Medical (NASDAQ:APYX) last issued its earnings results on Thursday, November 5th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.05. The firm had revenue of $14.03 million for the quarter, compared to the consensus estimate of $13.29 million. Apyx Medical had a negative return on equity of 76.60% and a negative net margin of 14.78%. Sell-side analysts expect that Apyx Medical Corporation will post -0.25 earnings per share for the current year.

Institutional Investors Weigh In On Apyx Medical

Several hedge funds have recently bought and sold shares of APYX. Nantahala Capital Management LLC acquired a new position in shares of Apyx Medical in the 2nd quarter valued at $14,683,414. AIGH Capital Management LLC purchased a new stake in Apyx Medical during the second quarter worth $5,066,000. BlackRock Inc. acquired a new stake in Apyx Medical during the second quarter valued at $2,519,000. Sei Investments Co. grew its position in Apyx Medical by 298.6% during the first quarter. Sei Investments Co. now owns 598,255 shares of the company’s stock valued at $2,208,000 after buying an additional 448,174 shares during the period. Finally, Renaissance Technologies LLC grew its position in Apyx Medical by 37.2% during the first quarter. Renaissance Technologies LLC now owns 302,395 shares of the company’s stock valued at $1,116,000 after buying an additional 82,000 shares during the period. Hedge funds and other institutional investors own 55.33% of the company’s stock.

About Apyx Medical

Apyx Medical Corporation develops and commercializes energy-based medical technologies for use in surgical and aesthetic procedures. The company’s platform is based on helium plasma technology, which is designed to deliver controlled energy for soft-tissue coagulation, cutting, and contraction.

Apyx Medical’s principal product line is Renuvion, a system that combines helium plasma with radiofrequency energy. Renuvion devices and handpieces are used by physicians in a range of surgical and aesthetic applications, including procedures intended to coagulate tissue and address skin laxity.